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Metastatic  breast  cancer  is incurable  by current  therapies  including  chemotherapy  and  immunother-
apy.  Accumulating  evidence  indicates  that  tumor-inﬁltrating  macrophages  promote  establishment  of
the lethal  metastatic  foci  and  contribute  to therapeutic  resistance.  Recent  studies  suggest  that  thevailable online 11 August 2015
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accumulation  of these  macrophages  is regulated  by a chemokine  network  established  in  the  tumor
microenvironment.  In this  perspective  paper,  we  elaborate  on the  chemokine  signals  that  can  attract
monocytes/macrophages  to the site of  metastasis,  and  discuss  whether  inhibition  of  these  chemokine
signals  can  represent  a new  therapeutic  strategy  for metastatic  breast  cancer.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  licensehemokine
. Introduction
Breast cancer is a leading cause of cancer death in women  largely
ue to metastasis that develop in the bone and lung. The 5-year
urvival of patients with metastatic disease drops to 21% whereas
hat of patients with early-stage breast cancer is 89–100% [1]. It
as been reported that 6–10% of breast cancer patients are found
o have metastasis at initial diagnosis and ∼30% of tumor-resected
atients develop distant metastases [2], indicating the failure of
urrent therapies and requirement of novel strategies to prevent
umor growth at the metastatic sites. Among potential new ther-
peutic targets are stromal cells, especially macrophages, within
he tumor microenvironment as they promote establishment of the
ethal metastatic tumors [3–6] and prevent the efﬁcacy of current
herapies [7–9].
In breast cancer mouse models, lung metastatic foci show
arked accumulation of a distinct macrophage population
F4/80+CD11b +Ly6C–) that is barely found in the normal lung
10] . In an experimental model of pulmonary metastasis, these
Abbreviations: MAM,  metastasis-associated macrophages; CSF-1, colony stimu-
ating factor-1; VEGF, vascular endothelial growth factor; CCL, CC-chemokine ligand;
CR, CC-chemokine receptor; IM,  inﬂammatory monocyte; CXCL, CXC-chemokine
igand; CXCR, CXC-chemokine receptor.
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ttp://dx.doi.org/10.1016/j.phrs.2015.08.004
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metastasis-associated macrophages (MAMs) are recruited to the
lung and directly contact with disseminating mammary tumor
cells within 24–48 h post-tumor injection, which enhances extrava-
sation of the circulating tumor cells and suppresses tumor
cell apoptosis [10,11]. Since genetic depletion of these CD11b+
macrophages reduces the metastatic tumor burden in the lung [10],
blockade of the MAM  accumulation is an attractive therapeutic
strategy for metastatic breast cancer.
It has been reported that the recruitment of macrophages to the
primary site is promoted by various cytokines and chemokines such
as colony stimulating factor-1 (CSF-1), vascular endothelial growth
factor (VEGF) and CC-chemokine ligand 2 (CCL2), although the
mechanisms underlying macrophage accumulation in the metasta-
sis sites are still largely unknown. We  have recently reported that
the accumulation of MAMs  at the metastatic lung is regulated by
chemokine ligands CCL2 and CCL3 and their respective receptors
CCR2 and CCR1 [12,13]. In this perspective paper, we describe the
roles of these chemokine signals in the MAM  accumulation, and
discuss therapeutic potential of their blockade for metastatic breast
cancer.
2. Accumulation of metastasis-associated macrophages via
chemokine signalsIt has been reported that high levels of CCL2 in breast cancer
specimens correlate with high number of macrophages in the pri-
mary tumors [14], suggesting pivotal roles of CCL2 in macrophage
recruitment to the tumor microenvironment. We  recently demon-
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Model for a chemokine cascade that promotes metastatic seeding of can-
cer cells. Cancer or host cell derived CCL2 promotes recruitment of inﬂammatory
monocytes (IMs) from circulation to the metastasis sites. These recruited IMs  differ-
entiate into metastasis-associated macrophages (MAMs) that express higher levels
of  CCR1. In the MAMs, CCL2-CCR2 signaling increases expression of CCL3. CCL3-
CCR1 autocrine signaling enhances and stabilizes cancer cell-MAM interaction in
part through integrin 4 binding to VCAM1 expressed on the tumor cell [11]. This
results in the retention of MAMs  that further promotes metastatic seeding of can-
cer  cells through at least in part conferring survival signals on the metastatic cell.
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cer showed therapeutic effects in 14 out of 43 patients with bonelue  and red arrows show CCL2 and CCL3 mediated events respectively. Dotted lines
ndicate secretion of chemokines.
trated that anti-CCL2 antibody treatment decreases the number
f MAMs  at the metastatic sites and reduces metastatic tumor bur-
en in an experimental model of breast cancer lung metastasis
12]. In this model, anti-CCL2 antibody treatment also inhibited
he migration of adoptively transferred inﬂammatory monocytes
IMs; CD11b+Ly6Chigh) to the tumor challenged lung. These results
ndicate that the CCL2-CCR2 signal recruits circulating IMs  to the
ite of metastasis where they differentiate into MAMs  and promote
stablishment of metastatic foci. We  have further found that the
AMs  isolated from the mouse lung with metastatic foci express
uch higher level of CCL3 compared with circulating IMs  [13].
nterestingly, the CCL3 expression in MAMs  is signiﬁcantly sup-
ressed by anti-CCL2 antibody treatment, suggesting that MAMs
ecrete high level of CCL3 once they differentiate from IMs  and this
s partly through activation of the CCL2-CCR2 signaling pathway.
enetic loss of host CCL3 or its receptor CCR1 reduces the MAM
ccumulation in the tumor-challenged lung 24 h after tumor injec-
ion and decreases number of metastatic foci. Loss of CCR1 also
revents MAM-cancer cell interactions and following retention of
AMs  in the tumor-challenged lung. These ﬁndings collectively
ndicate that activation of the CCL3-CCR1 axis in MAMs  via CCL2
ignaling promotes retention of MAMs  and subsequent metastatic
eeding of breast cancer cells (Fig. 1). These results suggest that
istinct chemokine receptors regulate speciﬁc process of the mono-
yte/macrophage accumulation, i.e., recruitment by CCL2-CCR2
nd retention by CCL3-CCR1 axis. Consistent with this suggestion,
n vitro studies show that migration, adhesion, and differentiation
f human monocytes are promoted by CCL2, CXCL18, and CXCL12
espectively [15–17].
In our breast cancer model, another CCL3 receptor CCR5 is
ot necessary for the early MAM  accumulation observed within
4 h after tumor injection. However, it is reported that CCR5 is
equired for macrophage accumulation in the lung foci after 7 days
f renal cancer cell injection [18], suggesting that macrophages
se different chemokine receptors to accumulate in the dis-
inct microenvironments at different phases of metastasis. Recent
tudies utilizing the PyMT mice suggest that a chemokine recep-
or predominantly used for macrophage accumulation might be
kewed by the induction of a speciﬁc ligand in the tumor microenvi-
onment. Namely, increased CCL2 level in the tumor by doxorubicin
reatment promotes CCR2 dependent monocyte recruitment [19],
lthough the PyMT mammary tumors normally recruit mono-
ytes/macrophages via CCR6 but not CCR2 [20,21] . Induction ofcal Research 100 (2015) 266–270 267
certain ligands in cancer cells as they progress may  also determine
the chemokine receptor required for the macrophage accumulation
since the primary tumors developed by mouse breast cancer cells
that overexpress CXCL12 or CX3CL1 recruit macrophages through
CXCR4 or CX3CR1 respectively [22,23]. In the primary tumors
developed by 4T1 mouse breast cancer cells, inhibition of either
CCR2 or CXCR2 can reduce the number of macrophages [24,25],
which also suggests the involvement of multiple chemokine signals
in the macrophage accumulation in the tumor microenvironment.
However, most of these ﬁndings come from in vitro systems or pri-
mary tumor models. Further studies are required to evaluate the
involvements of these chemokine signals other than CCL2 and CCL3
in the MAM  accumulation at the metastasis sites, as their actions
might represent therapeutic targets for metastatic diseases.
3. Inhibition of chemokine signals to prevent metastatic
outgrowth of beast cancer cells
The ultimate objective of macrophage-targeting therapy is with-
drawal of tumor-supporting and immunosuppressive microenvi-
ronment from the secondary sites by disrupting accumulation
and/or function of MAMs.  Accordingly, the above-mentioned
chemokine signaling molecules are potential targets for the treat-
ment of metastatic breast cancer.
Results from our breast cancer metastasis model suggest that
the inhibition of CCL3 secretion from MAMs  is one of the pos-
sible strategies as they are a major source of CCL3 among other
leukocytes such as neutrophils, T, B, and NK cells in the metastatic
lung [13]. CCL2 is another possible target ﬁtting this strategy since
CCL2 neutralizing antibody can suppress Ccl3 expression in MAMs
as well as their recruitment following mammary tumor metas-
tasis [12,13]. However, humanized monoclonal CCL2 neutralizing
antibody (CNTO888) is ineffective in suppressing serum CCL2 level
or tumor progression due to feedback mechanism that increases
CCL2 production [26]. Furthermore, discontinuing anti-CCL2 treat-
ment is reported to cause rebound inﬂux of monocytes into the
metastatic sites that enhances metastatic outgrowth [24]. These
reports suggest difﬁculty in suppressing MAM  accumulation by
CCL2 deprivation, and indicates requirement for another target. In
our model, the anti-CCL2 antibody treatment reduces CCL3 expres-
sion in MAMs  but inhibition rate is only 40% compared with IgG
treatment [13], suggesting that factors other than CCL2 from cancer
cells and/or tumor microenvironment also involve in CCL3 secre-
tion from MAMs.  It has been reported that CCL3 expression in
bone marrow-derived macrophages is increased by granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-33
[27,28]. Interestingly, chemokine ligands such as CCL5 and CCL18
can also promote secretion of various chemokines including CCL3
from cultured human monocytes [29,30]. These cytokines and
chemokines could be alternative targets to suppress CCL3 secre-
tion, although further studies are required to understand their
expression in metastatic sites and their contribution to MAM accu-
mulation.
Another possible strategy to suppress MAM  accumulation is
blockade of CCR1 and CCR2. Several companies have developed
small molecule inhibitors against CCR1 or CCR2 for rheuma-
toid arthritis or multiple sclerosis, and most of them are well
tolerated and show no adverse effects [31]. These antagonists
were developed for autoimmune diseases, and thus clinical trials
for cancer are very limited. Nevertheless, an anti-CCR2 antibody
(MLN1202) tested in a phase II clinical trial for metastatic can-metastases (ClinicalTrials.gov ID: NCT01015560). Most recently,
Chemocentryx initiated a phase Ib trial of their next-generation
CCR2 antagonist (CCX872) for non-resectable pancreatic cancer
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Fig. 2. Model for a chemokine network in the metastatic tumor microenvironment.
Chemokine gradients of CCL2, CCL5, and CCL18 formed by cancer cells or stromal
cells not only recruit IMs  and Treg cells toward the tumor microenvironment but also
establish another gradient of chemokine ligands (shown in different colors) such as
CCL3, CCL22, and CXCL8 that augments the accumulation of MAMs,  Treg cells, and
MDSCs. These overlapping gradients result in an evolving microenvironment that
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anhances tumor cell survival, growth and prevents immune attack. Consequently
isruption of these gradients suggests a possible therapeutic strategy for metastatic
isease.
ClinicalTrials.gov ID: NCT02345408). So far no clinical trials are
nderway for CCR1 antagonists in a cancer setting, however, a pre-
linical study indicates that CCR1 antagonist (BL5923) can suppress
etastatic tumor growth of colon cancer cells in the liver [32]. A
ecent report also shows that another CCR1 antagonist (CCX721)
educes tumor burden and osteolysis in a mouse model of mul-
iple myeloma bone disease [33]. Collectively, these data imply
hat therapeutic inhibition of CCR1 and CCR2 could be a novel
trategy to prevent metastatic tumor growth. Ccr1Ccr1−/−−/−−/−−/−
ice are healthy without any overt hematopoietic abnormali-
ies unless challenged with speciﬁc pathogens [34], suggesting
hat targeting CCR1 will not cause serious side effects. In contrast
cr2Ccr2−/−−/−−/−−/− mice show a reduced number of circulating
onocytes [35] perhaps indicating that CCR2 is a less attractive
arget than CCR1. However a CCR2 antagonist (CCX140-B) shows
herapeutic effect on type II diabetes in a phase II trial without
ffecting the blood monocyte count [36], suggesting that target-
ng CCR2 could remain as an important therapeutic strategy for
etastatic cancer.
Despite this optimism a treatment with single chemokine antag-
nist will almost certainly not be enough to suppress metastatic
umor growth since neither Ccr1Ccr1Ccr1 and Ccr2Ccr2Ccr2 deﬁ-
iency can achieve complete elimination of metastatic tumors in
he mouse model (maximum reduction rate was 60%) and model
ependent [13]. There might be two major reasons accounting for
his insufﬁciency, i.e., a redundancy of the target receptors and
 lack of direct effects on cancer cells. As described above, it iscal Research 100 (2015) 266–270
possible that multiple chemokine receptors such as CCR1, CCR2,
CCR5, CCR6, CXCR2, CXCR4, and CX3CR1 can be involved in the
MAM  accumulation. Interestingly, several studies have suggested
that in vitro monocyte migration induced by CCR1 or CCR2 acti-
vation is synergistically enhanced by activation of CXCR4 [37,38].
It is therefore possible that the above-mentioned receptors, in
particular CXCR4, cooperate with CCR1 and/or CCR2 to promote
MAM  accumulation and thereby metastatic tumor growth. Another
aspect to be considered is that tumor metastasis is supported
by MAMs  as well as other immune cell types such as myeloid-
derived suppressor cells (MDSCs) and regulatory T (Treg) cells that
are recruited via different chemokine signals [6]. For example,
Treg cells migrate towards primary ovarian tumors via CCL22-
CCR4 signal [39] and MDSCs accumulate in ovarian caner and
sarcoma by CXCL12 (a CXCR4 ligand) and CXCL8 (a ligand for
CXCR1/2) [40,41]. In the mammary tumors developed in mice,
CXCL5 (a CXCR2 ligand) and CCL5 (a ligand for CCR1/3/5) can
promote inﬁltration of MDSCs and Treg cells respectively [42,43],
although their roles at metastatic sites remain to be identiﬁed.
Considering such chemokine receptor redundancies, it may  be
necessary to block multiple chemokine signals to achieve full
therapeutic effects. This strategy seems to be practical since it is
possible to design a drug that can target more than one chemokine
receptor. So far, dual-antagonists for CCR1/CCR3, CCR2/CCR5, and
CCR2/CXCR2 have been developed and tested in animal mod-
els of acute and chronic inﬂammation [31]. However, clinical
application for metastatic breast cancer requires more investi-
gations of these synergies to identify combination of chemokine
signals that promotes metastatic tumor growth and to elucidate
therapeutic effects of the concomitant blockade of these sig-
nals.
Although breast cancer cells also express chemokine recep-
tors including CCR5, CCR7 and CXCR4 that enhance tumor cell
invasiveness and metastasis [44], it is unlikely that a single treat-
ment with chemokine antagonist can directly induce tumor cell
death. It will thus be essential to combine chemokine antago-
nists that target stromal cells with therapeutic modalities such
as chemotherapy or immunotherapy that directly kill the can-
cer cells. Several studies report that blockade of myeloid cell
recruitment by chemokine antagonists synergistically enhances
the therapeutic efﬁcacy of cytotoxic drugs. For example, genetic
loss of host CCR2 expression suppresses monocyte accumulation
and enhances the effect of doxorubicin or cisplatin treatment
on the relapse of mammary tumors in the PyMT mice [19].
A CCR2 antagonist (PF-04136309) also suppresses macrophage
accumulation in the primary tumor developed by orthotopically
injected pancreatic cancer cells, which enhances the effects of
gemcitabine on the tumor growth [45]. Furthermore, a CXCR4
antagonist (AMD3100) prevents macrophage accumulation and
delays tumor relapse after cyclophosphamide treatment in sub-
cutaneously transplanted lung cancer and in orthotopic mammary
cancers [46], and a CXCR2 (SB-265610) antagonist enhances ther-
apeutic effect of a doxorubicin/cyclophosphamide combination
treatment in a orthotopic breast cancer xenograft model probably
through inhibition of myeloid cell accumulation [47]. Inhibi-
tion of monocyte/macrophage accumulation may  also improve
immunotherapy efﬁcacy. In a pancreatic cancer mouse model,
pharmacological macrophage depletion enhances tumor reduction
induced by antibodies against T cell inhibitory receptors cyto-
toxic T-lymphocyte- associated antigen 4 (CTLA4) and programmed
cell death protein 1 (PD1) that augment tumoricidal CD8 + T cell
responses [48]. It is also reported that genetic depletion of CCR2+monocytes (CD11b+Ly6C+) enhances accumulation of adoptively
transferred CD8+ T cells in the primary tumor and thereby aug-
ments therapeutic effect of the adoptive T-cell therapy on the tumor
growth in a melanoma model [49]. Based on these ﬁndings, it
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ppears feasible to suppress metastatic tumor growth by combina-
ion therapy utilizing chemokine antagonists and cytotoxic drugs
r immunotherapeutic agents. Nevertheless, in order to bring these
pproaches into practical application, further studies are required
o elucidate the effects of macrophage-mediated chemokine sig-
als on the formation of chemoresistant or immunosuppressive
icroenvironment at the metastatic sites.
. Conclusion
Our data suggest that a gradient of CCL2 attracts mono-
ytes/macrophages towards the metastatic tumor microenviron-
ent where they are exposed to high levels of CCL2 and are
rompted to secrete another chemokine CCL3. As mentioned above,
uch a chemokine-induced chemokine secretion is also reported
n human monocyte culture systems, i.e., exposure to CCL5 or
CL18 induce secretion of CCL2, CCL3, CCL22, and CXCL8 [29,30]
hat can regulate accumulation of MAMs,  MDSCs and Treg cells.
nterestingly, mouse breast cancer cells used in our metastasis
odel can promote CCL5 expression in cultured macrophages
unpublished data). Furthermore, GM-CSF produced by human
reast cancer cell lines induces CCL18 secretion from cultured
acrophages [50], suggesting that macrophage-cancer cell inter-
ction establish gradients of these chemokines in the tumor
icroenvironment. Collectively these data suggest that gradients
f chemokines (e.g., CCL2, CCL5, and CCL18) formed in the tumor
icroenvironment not only recruit monocytes/macrophages but
lso form de novo chemokine gradients (e.g., ‘, CCL22, and CXCL8)
hat reinforce the accumulation of pro-metastatic immune cells
uch as MAMs,  MDSCs and Treg cells (Fig. 2). Since these pro-
etastatic chemokine signals are also involved in the pathology
f chronic inﬂammatory diseases, many companies have been
rying to develop selective or dual-blocking chemokine antago-
ists for chronic inﬂammatory diseases. To apply these drugs for
etastatic breast cancer, it is necessary to more clearly elucidate
he pro-metastatic chemokine network in the sites of metastasis
nd identify key links and synergistic effects within these gradients
hat are required for metastatic cells to alter their microenviron-
ent to prosper.
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